HIV coinfection with hepatitis c: Difference between revisions

	HIV coinfection with hepatitis c Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating HIV coinfection with hepatitis c from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
HIV coinfection with hepatitis c On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of HIV coinfection with hepatitis c All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on HIV coinfection with hepatitis c
CDC on HIV coinfection with hepatitis c
HIV coinfection with hepatitis c in the news
Blogs on HIV coinfection with hepatitis c
Directions to Hospitals Treating HIV coinfection with hepatitis c
Risk calculators and risk factors for HIV coinfection with hepatitis c

VisualWikitext

Latest revision as of 18:01, 18 September 2017

For main chapter on AIDS, click here

For main chapter on HIV, click here

For main chapter on Hepatitis C, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Overview

Pathophysiology

Causes

Differentiating HIV coinfection with hepatitis c from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

Template:WS Template:WH

@@ Line 1: / Line 1: @@
-{{Hepatitis C}}
+__NOTOC__
+{{HIV coinfection with hepatitis c}}
+'''For main chapter on AIDS, click [[AIDS|here]]'''
+'''For main chapter on HIV, click [[HIV|here]]'''
+'''For main chapter on Hepatitis C, click [[Hepatitis C|here]]'''
 {{CMG}}; {{AOEIC}} {{VK}}
-==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
+==[[HIV coinfection with hepatitis c overview|Overview]]==
-{{cquote|
-'''1.''' Anti-HCV testing should be performed in all HIV-infected persons ''(Class I, Level B)''.
+==[[HIV coinfection with hepatitis c pathophysiology|Pathophysiology]]==
+==[[HIV coinfection with hepatitis c causes|Causes]]==
-'''2.''' HCV RNA testing should be performed to conﬁrm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease ''(Class I, Level B)''.
+==[[HIV coinfection with hepatitis c differential diagnosis|Differentiating HIV coinfection with hepatitis c from other Diseases]]==
-'''3.''' Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy ''(Class I, Level A)''.
+==[[HIV coinfection with hepatitis c epidemiology and demographics|Epidemiology and Demographics]]==
-'''4.''' Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients  ''(Class I, Level A)''.
+==[[HIV coinfection with hepatitis c risk factors|Risk Factors]]==
-'''5.''' When possible, patients receiving [[zidovudine]] (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin ''(Class I, Level C)''.
+==[[HIV coinfection with hepatitis c natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
-'''6.''' HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation ''(Class IIa, Level C)''.}}
+==Diagnosis==
-==References==
+[[HIV coinfection with hepatitis c history and symptoms|History and Symptoms]] | [[HIV coinfection with hepatitis c physical examination|Physical Examination]] | [[HIV coinfection with hepatitis c laboratory findings|Laboratory Findings]]
-{{reflist|2}}
-{{WS}}
+==Treatment==
-{{WH}}
+[[HIV coinfection with hepatitis c medical therapy|Medical Therapy]] | [[HIV coinfection with hepatitis c prevention|Prevention]] | [[HIV coinfection with hepatitis c cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[HIV coinfection with hepatitis c future or investigational therapies|Future or Investigational Therapies]]
+==Case Studies==
+[[HIV coinfection with hepatitis c case study one|Case #1]]
-[[Category:Hepatitis|C]]
+==Related Chapters==
-[[Category:Gastroenterology]]
-[[Category:Infectious disease]]
-[[Category:Disease]]
-==References==
+* [[Coinfection]]
-{{reflist|2}}
+* [[AIDS]]
+* [[HIV disease]]
+* [[Hepatitis B with HIV coinfection]]
+* [[Tuberculosis and HIV coinfection]]
+* [[HIV and tuberculosis coinfection : drug interaction]]
+* [[HIV and pregnancy]]
+* [[Hepatitis]]
 {{WS}}
@@ Line 35: / Line 50: @@
 [[Category:Hepatitis|C]]
 [[Category:Gastroenterology]]
-[[Category:Infectious disease]]
 [[Category:Disease]]